Harrow (NASDAQ:HROW) Price Target Cut to $65.00 by Analysts at B. Riley

Harrow (NASDAQ:HROW - Get Free Report) had its target price cut by B. Riley from $69.00 to $65.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. B. Riley's target price indicates a potential upside of 176.36% from the stock's previous close. B. Riley also issued estimates for Harrow's Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at $0.17 EPS, Q3 2025 earnings at $0.21 EPS, Q4 2025 earnings at $0.38 EPS, FY2025 earnings at $0.78 EPS, FY2026 earnings at $2.67 EPS and FY2027 earnings at $4.79 EPS.

Separately, HC Wainwright reiterated a "buy" rating and set a $57.00 target price on shares of Harrow in a report on Monday, March 31st.

Harrow Trading Down 2.2 %

Shares of Harrow stock traded down $0.54 during trading hours on Tuesday, hitting $23.52. The company's stock had a trading volume of 520,963 shares, compared to its average volume of 504,940. The business has a fifty day moving average of $27.98 and a 200 day moving average of $37.36. Harrow has a 1-year low of $9.86 and a 1-year high of $59.23. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The company has a market capitalization of $838.58 million, a PE ratio of -25.02 and a beta of 0.46.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.14. The firm had revenue of $66.83 million during the quarter, compared to the consensus estimate of $66.01 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. As a group, equities analysts forecast that Harrow will post -0.53 EPS for the current year.

Remove Ads

Hedge Funds Weigh In On Harrow

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HROW. GF Fund Management CO. LTD. purchased a new stake in shares of Harrow during the fourth quarter worth about $25,000. Tower Research Capital LLC TRC increased its holdings in Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after purchasing an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC purchased a new stake in Harrow during the 4th quarter worth approximately $78,000. AlphaQuest LLC raised its position in shares of Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock valued at $118,000 after purchasing an additional 2,889 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Harrow during the 3rd quarter valued at approximately $271,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.